Table 1.

Clinical trials of adoptive cell therapy in patients with glioblastoma.

Patient number	Responsible party	Type of cells used	Phase	NCT no.	Status	Results
14	Nabil Ahmed, Baylor College of Medicine	Anti-HER2 CAR T cells	I	NCT02442297	Recruiting	None
51	City of Hope Medical Center	Anti-HER2 CAR T cells	I	NCT03389230	Recruiting	None
16	Baylor College of Medicine	Anti-HER2 CAR T cells	I	NCT01109095	Completed	(61)
10	RenJi Hospital	Anti-EGFR CAR T cells	I	NCT02331693	Recruiting	None
60	Fuda Cancer Hospital, Guangzhou	Anti-GD2 CAR T cells	I, II	NCT03252171	Completed	None
60	Fuda Cancer Hospital, Guangzhou	Anti-EphA2 CAR Tcells	I, II	NCT02575261	Completed	None
50	Qingtang Lin, Xuanwu Hospital, Beijing	Anti- Her-2, EGFRVIII, IL13Rα2, EphA2, GD2 CD133 CAR T cells	I	NCT03423992	Recruiting	None
107	National Cancer Institute	Anti-EGFRvIII CAR T cells	I, II	NCT01454596	Completed	(65)
3	Duke University	Anti-EGFRvIII CAR T cells	I	NCT02664363	Active, not recruiting	None
24	Duke University	Anti-EGFRvIII CAR T cells	I	NCT03283631	Recruiting	None
20	Beijing Sanbo Brain Hospital	Anti-EGFRvIII CAR T cells	I	NCT02844062	Recruiting	None
92	City of Hope Medical Center	Anti- IL13Rα2 CAR T cells	I	NCT02208362	Recruiting	(66)
20	Beijing Sanbo Brain Hospital	Anti-PD-L1 CSR T cells	I	NCT02937844	Recruiting	None
332	National Cancer Institute	TILs	II	NCT01174121	Recruiting	None
10	University of Colorado, Denver	TILs	I	NCT00002572	Completed	None
83	Hoag Cancer Center, Newport Beach	LAK	II	NCT00331526	Completed	(46)

Data from: ClinicalTrial.gov 09/10/2019.